7: Treatment of osteoporosis: Why, whom, when and how to treat

Medical Journal of Australia

Volumn 180, Issue 6, 2004, Pages 298-303

  Seeman, Ego ^a   Eisman, John A ^b  

^a AUSTIN HEALTH   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANABOLIC AGENT; CALCITONIN; CALCIUM; CORTICOSTEROID; DRUG METABOLITE; ETIDRONIC ACID; FLUORIDE; HORMONE; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; STRONTIUM; STRONTIUM RANELATE; UNCLASSIFIED DRUG; VITAMIN D;

ARTICLE; BONE STRENGTH; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FRAGILITY FRACTURE; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; LIFESTYLE; ORTHOSIS; OSTEOPENIA; OSTEOPOROSIS; RISK ASSESSMENT; RISK REDUCTION; SCREENING TEST; SEX DIFFERENCE; VERTEBRA FRACTURE;

EID: 1642401284     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb05931.x     Document Type: Article

References (18)

1. Sambrook PN, Phillips SR, Seeman E, Ebeling PR. Preventing osteoporosis: Outcomes of the Austrilian Fracture Prevention Summit. Med J Aust 2002; 176 (8 Suppl): S1-S16.
2. Randell A, Sambrook PN, Nguyen TV, et al. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int 1995; 5: 427-432.
3. Sanders KM, Nicholson GC, Ugoni AM, et al. The increasing health burden of hip and other fractures in Austrilia. Med J Aust 1999; 170: 467-470.
4. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporosis fractures in men and women: An observational study. Lancet 1999; 353: 878-882.
5. Seeman E. The dilemma of osteoporosis in men. Am J Med 1995; 98: 75S-87S.
6. Mosekilde L. Consequences of the remodelling process for vertebral trabecular bone stracture: A scanning electron microscopy study (uncoupling of loaded structures). Bone Miner 1990; 10: 13-35.
7. Seeman E. Pathogenesis of bone fragility in women and men. Lancet 2002; 359: 1841-1850.
8. Keaveny TM, Morgan EF, Niebur GL, Yeh OC. Biomechanics of trabecular bone. Annu Rev Biomed Eng 2001; 3: 307-333.
9. Fyhrie DP, Schaffler MB. Failure mechanisms in human cancellopus bone. Bone 1994; 15: 105-109.
10. Delmas PD. Treatment of osteoporosis. Lancet 2002; 359: 2018-2026.
11. Seeman E, Delmas PD. Reconstructing the skeleton with intermittent parathyroid hormone. Trends Endocrine Metab 2001; 12: 281-283.
12. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium renelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-468.
13. Cranney AS, Guyatt G, Griffith L, et al. Summary of meta-analysis of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570-578.
14. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
15. Parker MJ, Gillespie LD, Gillespie WJ. Hip protectors for preventing hip fractures in the elderly. Cochrane Database Syst Rev 2003; (3): CD001255.
16. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320-323.
17. Kenis JA, Johnell O, Black DM, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 2003; 33: 293-300.
18. Nguyen TV, Center JR, Elsman J. Osteoporosis in elderly men and women: Effects of dietary calcium, physical activity and body mass index. J Bone Miner Res 2000; 15: 322-331.